Amneal Pharmaceuticals has launched FOCINVEZ, a groundbreaking ready-to-use injectable version of fosaprepitant, making it the first of its kind in the market. Unlike other versions of fosaprepitant, FOCINVEZ does not require reconstitution or dilution, eliminating the need for additional steps and minimizing the risk of medication errors. Moreover, this single-dose vial product is free of Polysorbate 80, addressing concerns associated with allergic reactions. FOCINVEZ is indicated for use in both adults and pediatric patients aged six months and older, offering a versatile solution for different healthcare settings.